Figures computed from official regulatory filings — .
Analysttarget 21.73 USD (+24%) · consensus 3.25/5 · 7 buy · 12 hold · 5 sell
Ownershipinsiders 4.89% · institutions 104.07% · short 28.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Sarepta Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
102 buys188 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Estepan Ian Michael | Other | $551K | SEC |
| Wong Ryan Ho-Yan | Other | $294.9K | Unusual size | SEC |
| Rodino-Klapac Louise | Other | $476K | SEC |
| Rothfuss Cristin | Other | $489.4K | Unusual size | SEC |
| SEVERINO MICHAEL | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SEVERINO MICHAEL | Award | n/a (No price was disclosed in the filing) | SEC |
| Wigzell Hans Lennart Rudolf | Award | n/a (No price was disclosed in the filing) | SEC |
| Nicaise Claude | Award | n/a (No price was disclosed in the filing) | SEC |
| Barry Richardtrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| Chambers Michael Andrewtrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| BEHRENS M KATHLEENtrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| Connelly Deirdre P | Award | n/a (No price was disclosed in the filing) | SEC |
| Boor Kathryn Jean | Award | n/a (No price was disclosed in the filing) | SEC |
| Mayo Stephen | Award | n/a (No price was disclosed in the filing) | SEC |
| Rodino-Klapac Louise | Other | $16.1K | SEC |
| Estepan Ian Michael | Other | $18.7K | SEC |
| Rothfuss Cristin | Other | $16.6K | SEC |
| Mayo Stephen | Sell | $123.2K | SEC |
| Wong Ryan Ho-Yan | Other | $4.4K | SEC |
| Rothfuss Cristin | Other | $8.2K | SEC |
| Wong Ryan Ho-Yan | Other | $2.7K | SEC |
| Estepan Ian Michael | Other | $9.9K | SEC |
| Rodino-Klapac Louise | Other | $15.2K | SEC |
| Rodino-Klapac Louise | Other | $8.5K | SEC |
| Rothfuss Cristin | Other | $5.9K | SEC |